Australia markets closed

Medlab Clinical Limited (MDC.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.1500-0.0050 (-3.23%)
At close: 04:10PM AEDT
Full screen
Previous close0.1550
Open0.1500
Bid0.1500 x 3519200
Ask0.1550 x 165200
Day's range0.1500 - 0.1550
52-week range0.1400 - 0.4200
Volume83,327
Avg. volume237,469
Market cap51.326M
Beta (5Y monthly)1.32
PE ratio (TTM)N/A
EPS (TTM)-0.0420
Earnings date22 Feb 2022 - 28 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est0.42
  • GlobeNewswire

    Nanocelle® Patent Granted in Usa

    Medlab receives Granted Patent Protection for NanoCelle® in the USA by US Patent & Trademark Office (USPTO) SYDNEY, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Medlab Clinical Ltd (ASX: MDC) is extremely pleased to announce the USPTO has granted patent protection for NanoCelle® “Transmucosal and transdermal delivery systems” (Patent No. 11160753) in the United States of America. This announcement follows just three weeks after announcing the ‘Notice of Allowance’ received by the USPTO. (October 06, 2021).

  • GlobeNewswire

    DEPRESSION PATENT FOR OROTATE APPROVED & GRANTED BY US PATENT OFFICE

    SYDNEY, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Medlab Clinical LTD (ASX:MDC) is pleased to announce the Orotate patent, specifically to addressing depression in United States of America has been granted. The United States Patent and Trademark Office (USPTO) has applied a Patent term to 28 MAY 2037 with a US patent number 11,135,181. Previously Medlab announced [5 Jul 2021] final trial readouts for its phase 2 Depression trials.Orotate use as a drug substance was key to the investigative product “NRGB

  • GlobeNewswire

    NANOCELLE “ISSUE OF ALLOWANCE” BY US PATENT OFFICE

    SYDNEY, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Medlab Clinical LTD (ASX.MDC) is pleased to announce NanoCelle® the company’s proprietary delivery platform has been issued a “Notice of Allowance” by the USPTO (United States Patent and Trademark Office). Pursuant to the Notice of Allowance, fees associated with the patent have been paid and MDC is expecting to receive GRANT Status with US patent numbers and expiry dates within the next 4 weeks. Dr Sean Hall, CEO of MDC said “after approximately 4 years